Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Membrane Fraction) | PTGER2 Membrane Fraction (HEK293 Expressed). Native conformation, Endotoxin <1EU/µg. Sequence Verified. | View PTGER2 Products |
| Gene Delivery (Lentivirus/ORF) | PTGER2 Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable cell lines preserving intact GPCR conformation. | View PTGER2 Products |
| Benchmark Control | Anti-PTGER2 Recombinant Antibody (Clinical Benchmark). Positive control for flow cytometry binding and screening assays. | View PTGER2 Products |
| Validator | PTGER2 siRNA Set. For knockdown verification and assay specificity. | View PTGER2 Products |
| Related Target: PTGER4 | EP4 Receptor. Compensatory PGE2 pathway; essential for dual-targeting or selectivity screening. | View PTGER4 Products |
| Related Target: PTGS2 | COX-2. Upstream PGE2 synthesis; pathway logic for combination therapy. | View PTGS2 Products |
| Related Target: PDCD1 | PD-1. Synergistic target for immune checkpoint combination therapies. | View PDCD1 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR Conformation for Binding Assays | HEK293 Membrane Fraction & Lentivirus Stable Cell Lines preserve native topology; Sequence Verified. |
| Functional Antagonist/Agonist Screening (cAMP/Gs) | High-titer Lentivirus enables Gs-cAMP assay development in host cell lines. |
| EP Subfamily Selectivity (vs EP4/EP1/EP3) | Human/Mouse/Cyno ortholog reagents available; Sequence Verified ORFs for all EP family for rigorous counter-screening. |
| Assay Specificity & False Positives | PTGER2 siRNA included for target knockdown validation; Validated siRNA sets for specificity confirmation. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies included for assay standardization. |
Live PTGER2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTGER2 therapeutics is intensifying, with major players shifting focus from traditional COX-2 inhibition to receptor-specific modulation. As first-generation EP2 agonists establish efficacy in ocular hypertension and first-generation immuno-oncology therapies reach clinical maturity, the next wave of R&D is targeting the PGE2/PTGER2 axis to overcome immunosuppression in the tumor microenvironment, addressing therapy-refractory solid tumors through selective EP2 antagonism and dual EP2/EP4 blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Tempest Therapeutics (TPST-1495), Ono Pharma, Eicos Sciences | Solid Tumors, Inflammation, Immunotherapy Combo | cAMP Functional Assay; Receptor Selectivity (Need high-expression PTGER2 cell lines via Lentivirus and EP1-4 panels) |
| Small Molecule Agonist | Ube Industries / Santen (Omidenepag), Various Ophthalmic Biotechs | Glaucoma, Ocular Hypertension, Tissue Repair | Gs Signaling Bias Assay; cAMP/Functional Activation (Need native conformation membrane fractions or intact cell lines) |
| Monoclonal Antibodies | Emerging Biotechs | Inflammation, Oncology | Binding Assays on Native Targets (Need overexpressing cell lines) |
| Combination (PD-1 + EP2/EP4i) | Academic / Industry Collaborations | Refractory Cancers | Dual Target Cell Lines (PTGER2 + PD-L1 co-expression Lentivirus-ready) |